Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.98 [0.9, 1.07]
Studies not reported
High
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Non‐vertebral fractures · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes non‐vertebral fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.54 [0.22, 1.35]
Studies not reported
Very low
Hip Fracture · postmenopausal women at lower risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Wrist fractures · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in wrist fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.48 [0.03, 7.5]
Studies not reported
Low
Withdrawals due to adverse events · postmenopausal women at lower risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.38, 1.18]
Studies not reported
Low
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Clinical vertebral fractures · pPostmenopausal women at higher risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Non‐vertebral fractures · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day probably leads to lower non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.8 [0.72, 0.9]
Studies not reported
Moderate
Hip Fracture · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.73 [0.56, 0.94]
Studies not reported
Low
Global evaluation · otherwise healthy adults and children with common cold symptoms
Antihistamine‐decongestant probably leads to lower global evaluation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: all · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant leads to higher adverse effects: all compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness, and other central nervous system adverse effects · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: drowsiness, hypersomnia, lethargy, excessive… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: dry mouth · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: dry mouth compared with placebo (low certainty).
1 finding from 1 review
Gastrointestinal adverse events · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: gastrointestinal compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: dizziness, lightheadedness · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant leads to higher adverse effects: dizziness, lightheadedness compared with placebo (high certainty).
1 finding from 1 review
Global evaluation · otherwise healthy adults and children with common cold symptoms
Antihistamine‐analgesic‐decongestant showed no clear difference in global evaluation: after 3 days of treatment (included children 2 to… compared with placebo (low certainty).
2 findings from 1 review
Global evaluation: after 5 days of treatment (included children 2 to 12 years old only) · otherwise healthy adults and children with common cold symptoms
Antihistamine‐analgesic‐decongestant showed no clear difference in global evaluation: after 5 days of treatment (included children 2 to… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: all · otherwise healthy adults and children with common cold symptoms
Antihistamine‐decongestant showed no clear difference in adverse effects: all compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: drowsiness, hypersomnia, and excessive sleepiness · otherwise healthy adults and children with common cold symptoms
Antihistamine‐decongestant showed no clear difference in adverse effects: drowsiness, hypersomnia, and excessive sleepiness compared with placebo (low certainty).
1 finding from 1 review